Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Peptide Therapeutics market size was estimated at USD 39.6 billion in 2021 and is expected to surpass around USD 68.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.4% during the forecast period 2022 to 2030.

Key Takeaways:

• By Type, the U.S. Peptide Therapeutics market was valued at USD 16.9 Billion in 2021 and expected to witness growth at a CAGR of 5.8% from 2022 to 2030.
• By application, cancer held the second-largest revenue share in 2021 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
• The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
• By type of manufacturers, the outsourced segment is expected to expand at a lucrative CAGR of 6.6% over the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
• By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
• North America held the largest share in terms of revenue in 2021 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives
• Asia Pacific is expected to register a lucrative growth rate of 8.7% over the forecast period. The presence of an established generic industry and API providers in this region, coupled with the growing economic stability in some of the countries, is expected to propel market growth

The rising incidence of cancer as well as metabolic disorders such as osteoporosis, obesity, and diabetes will drive the adoption of peptide therapeutics during the forecast period. Due to the sheer growing number of affected pediatric patients and the pervasiveness of target diseases in low-income countries, there is a high demand for efficient and low-cost drugs.

Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Report Scope of the Peptide Therapeutics Market

Application Insights

In 2021, the metabolic segment dominated the market with a revenue share of over 35.5%. The prevalence of metabolic disorders is rapidly increasing. Sedentism, unhealthy eating habits, and excessive alcohol consumption have all contributed to an increase in the incidence of these disorders. Furthermore, the growing geriatric population susceptible to metabolic disorders is expected to provide a potential growth platform for the market.

Cancer emerged as the second-largest segment in 2021. The significant components responsible for this segment growth are rising cancer prevalence worldwide and increased prescription of peptide therapeutics for cancer treatment. Increased demand for efficient and fast-acting therapeutics is expected to fuel growth during the forecast period. Moreover, increased awareness among healthcare providers and patients about the side effects of chemotherapy and radiation therapy is a primary factor influencing the growth of alternative therapeutics like peptide-based drugs. The aforementioned reason is expected to propel the growth of the cancer segment. Furthermore, the presence of a strong product pipeline is expected to validate progress.

Type Insights

The innovative segment dominated the market in 2021 with a revenue share of over 60.2% owing to the increased R&D investments by large pharmaceutical companies in the discovery and development of new drugs and high prescription rates. The market is divided into generic and innovative segments based on type.

The generic segment is expected to grow at a rapid pace during the forecast period. Rising healthcare spending and increased federal government healthcare spending are expected to drive generic drug adoption. The loss of patents on many branded drugs is also believed to be a key factor driving the generic segment. The loss of a patent is viewed as a significant opportunity for generic players to enter the market with low-cost alternatives to blockbuster drugs. However, in the case of some innovative drugs, brand loyalty may have an impact on segment growth.

Type of Manufacturers Insights

The in-house manufacturing segment held the largest revenue share of over 65.1% in 2021. Most of the key players are involved in developing peptide therapeutics in-house owing to stringent regulations and the high cost of outsourcing. As large pharmaceutical companies have proper infrastructure for large-scale production and advanced technology, these companies prefer in-house manufacturing. 

The outsourcing activities for manufacturing are also estimated to grow during the forecast period due to difficulties in manufacturing therapeutics with high-quality standards. The companies prefer to outsource the Active Pharmaceutical Ingredient (API) from companies having high-end technology and expertise for manufacturing various types of peptides.

Peptide manufacturing is a complex procedure and it requires advanced technologies such as Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), or Hybrid for purification and synthesis of high-quality products, which results in the high cost of manufacturing. Besides, increasing R&D funding and capital investments by key players by entering into strategic agreements are anticipated to result in the market growth in the forecast period.

Route of Administration Insights

The parenteral route of administration dominated the market in 2021 with a revenue share of over 80.4%. This is attributed mainly to the high adoption rate, faster delivery of drugs, and ease of application. The biopharmaceuticals giants are continuously exploring new methods of drug delivery pertinent to peptides. Novel drug delivery technologies are now being assessed for efficacy with engineered molecules having advanced PEGylation in an attempt to improve drug delivery performance and patient compliance through better modes of drug delivery. Patient compliance and acceptability are major advantages of the oral route of drug administration. However, enzymatic degradation that inhibits blood absorption of these drugs holds a major disadvantage.

The pulmonary route is acknowledged for peptide and protein administration owing to the physiological characteristics of the respiratory system. Several proteins and peptides are currently undergoing clinical trials and awaiting approval via pulmonary usage. However, low bioavailability and lower molecular weighing molecules crossing alveolar epithelium causing inflammation are major usage barriers.

Synthesis Technology Insights

The LPPS segment dominated the market with a share of over 45.2% in 2021 owing to the rising demand for pure peptides for the development of efficient therapeutics. However, issues such as higher consumption of time are responsible for shifting consumers’ preferences to faster and more effective methods such as SPPS. 

SPPS lowers the synthesis time and is used in a wide range of production procedures. Moreover, higher efficiency during the synthesis of longer peptides is another driver for the market. Furthermore, associated automation, scalability, and enhanced control over the physicochemical properties of peptides are expected to drive the market over the forecast period.

Hybrid technology is expected to witness lucrative growth in the years to come owing to associated benefits such as compatibility with both liquid-phase synthesis and solid-phase synthesis. Companies are investing in R&D to incorporate the benefits of both LPSS and SPSS and provide a cost-effective and sustainable solution. Hybrid technology is expected to expand at a lucrative CAGR of 8.1% over the forecast period owing to a high adoption rate.

Regional Insights

North America dominated the market in 2021 with a revenue share of over 45.2%. The rise in peptide therapeutics product awareness, rising demand for diagnostics in cancer and other diseases, and the expanding biotechnology industry are key factors contributing to the regional market growth. Increased government R&D spending is also expected to assist peptide therapeutics to maintain their primacy in the forecast period. This region's well-established biopharmaceutical and pharmaceutical industry is a major factor fueling the growth. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected in the U.S. in 2022. Cancer is the second leading cause of death in the country, trailing only heart disease.

This data suggests that peptides will become more prominent in the healthcare business in the U.S. and it will progress through clinical trials. Moreover, the demand for peptide therapeutic approaches is expected to rise as cancer becomes more widespread. The Asia Pacific is anticipated to witness significant growth over the forecast period due to high untapped opportunities, minimal raw material costs, a growing base of companies offering outsourcing services, a thriving biotech industry, and increased R&D investments. The lower cost of raw materials and the patent expiration of blockbuster drugs are anticipated to enhance the generic market in the near future, providing significant growth potential.

Some of the prominent players in the Peptide Therapeutics Market include:

• Eli Lilly and Company
• Pfizer, Inc.
• Amgen, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceuticals Industries Ltd.
• Lonza Inc.
• Sanofi
• Bristol-Myers Squibb (BMS)
• AstraZeneca PLC
• GlaxoSmithKline plc (GSK)
• Novartis AG
• Novo Nordisk A/S

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Peptide Therapeutics market

• Application

• Cancer
• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others
• Type
• Generic
• Innovative
• Type of Manufacturers
• In-house
• Outsourced
• Route of Administration
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others
• Synthesis Technology
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Peptide Therapeutics Market Study:

• Growth of Peptide Therapeutics in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Peptide Therapeutics and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Peptide Therapeutics Consumption Analysis
•  Peptide Therapeutics Production Analysis
•  Peptide Therapeutics and Management